BioLineRx Ltd. Stock Price: Quote, Forecast, Splits & News (BLRX)

BLRX

BioLineRx Ltd.

BLRX

Overview

Financials

Historical Data

$4.25

-$0.32

Jun 20, 12:17:56 PM EDT

Change

-$0.32

Financial Profile

Prev Close

$4.57

Market Cap

$339.39M

Day Range

$4.25 - $4.67

Open

$4.62

P/E Ratio

-0.7

52W Range

$2.30 - $35.60

24H Volume

$144.70K

Dividend Yield

0.00%

EPS

-6.00

Key Issues

Latest Price Movement

Jun 20

Recent Transcripts

Q1 2025 marked cost reductions, strong cash runway, and Effexxa royalty revenue growth.

BioLineRx secured a transformative licensing deal, streamlining operations and extending cash runway into 2026.

Mar 31

Q4 2024

Licensing Agreement

$10M upfront, $87M milestones, 18-23% royalties

Cash Runway

Extended to 2026

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. Reported revenue and EPS data from Earnings powered by FinChat.io. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice.

Market Cap: $339M
IPO Date: 7/27/11
CEO: Mr. Philip A. Serlin CPA, CPA, M.B.A., MBA
Fulltime Employees: 28
Sector: Healthcare
Industry: Biotechnology
Country: IL
Exchange: NASDAQ Capital Market

Peers

$0.00

Watchlist

$0.00

BioLineRx Ltd. Stock Price: Quote, Forecast, Splits & News (BLRX)

Perplexity Finance

BLRX

BioLineRx Ltd.

BLRX

Overview

Financials

Historical Data

$4.25

-$0.32

Jun 20, 12:17:56 PM EDT

Change

-$0.32

Financial Profile

Prev Close

$4.57

Market Cap

$339.39M

Day Range

$4.25 - $4.67

Open

$4.62

P/E Ratio

-0.7

52W Range

$2.30 - $35.60

24H Volume

$144.70K

Dividend Yield

0.00%

EPS

-6.00

Key Issues

Latest Price Movement

Jun 20

Earnings

Report Date

May 27, 2025

Reported Revenue

11.7M

Beat +543.08%

Avg 1d Change

4.57%

Report Period

Q1 2025

Reported EPS

1.4

Beat +265.48%

Implied Move 1d

85.08%

Transcript

9m 41s

Thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a six ks. I'd like to remind you that certain statements we make during the call will be forward looking. Because such statements deal with future events, and are subject to many risks and uncertainties actual results may differ materially from those in the forward looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20 F and our quarterly reports on Form six ks that are filed with the U. S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.

10m 37s

Thank you Irina and good morning everyone. And thank you for joining us on today's call. As has been our practice, I will begin with a few prepared remarks before turning the call over to Mali Zebi, our Chief Financial Officer to briefly recap our financials. Afterwards, we will take your questions. Ella Sarani, our Chief Development Officer is also available for Q and A. In November of last year we announced a transformational exclusive Outly agreement Aramid Pharma Limited. Agreement gives Aramid the rights to commercialize Effexxa our FDA approved stem cell mobilization agent indicated in combination with G CSF for the collection and subsequent autologous transplantation in patients with multiple myeloma. The agreement covers all indications excluding solid tumor indications and in all territories other than Asia. In exchange, we received an upfront payment as well as potentially significant commercial milestones and royalties. Recall that we successfully shepherded Effexxa also known as fortide, through clinical development and FDA approval in September 2023. We believe AIRMED is the ideal partner EFEXTA given that team's track record of success. As a reminder, the current AIRMID team established AMRID Bio in two thousand and to focus on rare diseases and in less than eight years they grew AMERIT revenue to an annual run rate of several hundred million dollars ultimately selling the company for approximately $1,500,000,000 In addition, the Aramid commercial portfolio also includes Omnisurge.

12m 17s

The first and only FDA approved nicotinamide NAM modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. So the addition of Effexxa is very complementary. And while it has taken a few months to complete the transition, Effexxa has returned to growth and is performing well under Aramid stewardship. And I believe it will contribute incremental long term value to our company through the potential milestones and royalties just mentioned. This transaction enabled us to return to our roots as a highly innovative company in complex drug development. With a very experienced team and a validated track record of clinical and regulatory success. Since that announcement we have been laser focused on evaluating early clinical stage and late preclinical stage therapeutic assets in oncology and rare disease. That will allow us to leverage our expertise in drug development and expand our pipeline. I am pleased to report that we continue to evaluate several promising candidates that fit our criteria. Importantly, subsequent development of any candidates that we identify have efficient and clearly defined clinical development paths and will be partly funded through milestones and royalties from our license agreement. With Aramid as well as our previously announced agreement with Gloria Bio.

13m 37s

We continue to conduct due diligence and advanced discussions with a number of parties and I am optimistic that we'll make a definitive announcement later this year. The airman agreement also covers ongoing development of Afexta in patients with sickle cell disease undergoing gene therapy. Stem cell mobilization is a challenge for many sickle cell disease patients. As currently available gene therapies for sickle cell disease rely on the collection of significant quantities of c d 34 positive hematopoietic stem cells and this collection process often requires multiple sessions. Which adds cost and complicates the patient journey. In addition, many patients are ineligible for stem cell transplantation because they are unable to mobilize the required numbers of cell cells for successful transplant. Hematopoietic stem cell transplantation after genetic modification is potentially curative for patients with sickle cell disease. And we eagerly await results from two phase one investigator initiated trials that are ongoing. The first sickle cell disease trial is being sponsored by Washington University in St. Louis. An abstract detailing the initial results from this proof of study was presented at the sixty sixth Annual American Society of Hematology annual meeting last December. The findings suggest that patients with sickle cell disease given metixafortide alone in combination with natalizumab can mobilize and potentially collect a number of stem cells required for a gene therapies in a single apheresis cycle.

15m 11s

The second sickle cell disease trial is being sponsored by St. Jude Children's Research Hospital in Memphis and is being executed by some of the leading sickle cell disease researchers in the world. As a result of the AIRMET agreement and the transition of several members of the FormBioLineRx commercial team to AIRMET, Late last year, we announced the shutdown of our U. S. Operations and we also implemented a headcount reduction in Israel where BioLineRx continues to be based. Together these actions have allowed us to reduce our ongoing operating cash burn by over 70% from over $40,000,000 annually to less than $12,000,000 as we entered 2025 including a $10,000,000 financing that we completed in January we ended the first quarter on a firm financial footing with cash of $26,400,000 and a cash runway projected to fund our operations through the second half of twenty twenty six. Turning now to pancreatic cancer or PDAC. We are continuing to support the development of metixaportide in this indication. Recall that metixafortide is an inhibitor of CXCR four, which plays a critical role in establishing and maintaining tumors. It is highly expressed in over 20 different tumor types, and it is estimated that greater than seventy percent of PDAC patients show an overexpression of CXCR four.

16m 35s

PD-one and PD L1 inhibitors have demonstrated significant efficacy in multiple solid tumor types but no survival benefit in PDAC. In contrast, we previously completed a phase two trial second line PDAC patients with metixafortide plus a PD one inhibitor plus standard of care chemotherapy. That demonstrated improvements across all study endpoints. So while PDAC is an inherently challenging cancer to treat, there is very strong scientific rationale for continued development by us this area. To that end, a randomized Phase 2b PDAC trial sponsored by Columbia University and supported by both Regeneron and BioLineRx known as chemo four panc, continues to enroll patients. To further accelerate enrollment, last quarter Columbia activated additional trial sites and the trial is planned to be fully enrolled in 2027. A prespecified interim analysis is planned for when forty percent of PFS events are observed which is planned for 2020 Results from this trial, if positive, could be a significant value in inflection point. For our company. And signal new hope for patients suffering from this very challenging tumor type. We look forward to keeping you up to date on our progress with this important program. And staying on the topic of the Columbia University PDEC study for a moment, we were very pleased to announce that an abstract detailing new data from the pilot phase of the chemo med penc trial has been accepted for presentation at the twenty twenty five annual meeting of the American Society Clinical Oncology or ASCO.

18m 14s

The presentation will take place at 9AM Central Daylight Time on Saturdays, May 31. Recall that in data previously presented seven of the 11 patients in the pilot study experienced a partial response with six of those responses confirmed. That equates to a partial response rate of sixty four percent which compares very favorably to the historical partial response rate of twenty three percent. Ten of eleven patients or ninety one percent exhibited disease control, which also compares very favorably to to a historic disease control rate of forty eight percent, a Additionally, median PFS progression free survival was nine point six months compared to historic median PFS of five five months. Notably, analysis of the biopsy samples demonstrated a significant increase in CD eight positive T cell density in tumors from all eleven patients treated. Suggesting the ability of the metixafortide combination to overcome the immunosuppressive mechanisms with the tumor microenvironment that render other treatments ineffective. In the updated data to be presented at ASCO on Saturday, four patients have now been progression free for over a year. Two patients underwent definitive treatment for metastatic PDAC. One had complete resolution of all radiologically detected liver lesions and underwent definitive radiation the primary pancreatic tumor.

19m 41s

While the other had a sustained partial response and underwent pancreatic codua de pathology demonstrating a complete response. Recall that it was due to these exceptional results from the pilot phase that the chemo for METPANK phase two trial was amended to become the current on ongoing randomized study with planned enrollment increasing from 30 patients to a hundred and eight patients. Suffice it to say that we continue to be very excited about the data emerging from this program. In summary, with potential revenue from AIRMET together with a significantly streamlined organization and a strengthened balance sheet we believe we are very well positioned to advance Matixa fortide in solid tumor indications such as pancreatic cancer while evaluating [indiscernible] additional assets in oncology and rare disease. Our goal continues to be to help as many patients as possible while enduring value for our shareholders. Before turning the call over to Molly to review our financials in more detail, I'd like to briefly touch on Effexis performance in the first quarter. After a brief transition period in late twenty twenty four and early twenty twenty five, the AIRMET team has made very encouraging progress in driving effects sales generating sales of $1,400,000 in Q1 twenty twenty five which resulted in $300,000 of royalty revenues to BioLineRx, We anticipated some modest and temporary softness in FX to sales in the first part of Q1 as a result of the transition to AIRMID.

21m 12s

However, we have now seen it return to growth in late Q1 and early Q2. Now let me turn the call over to Molly provide a financial update. Molly, please go ahead.

21m 24s

Thank you, Phil. It is our practice.

21m 26s

I will only go over the most significant items in our financial statement. Revenues, cost of revenues, research and development expenses, sales and marketing expenses, net loss, and cash.

21m 40s

I invite you to review the six ks filing we made this morning which contains our financials, and press release. [indiscernible] revenues for the quarter ended March 31, 2025 were $300,000 as compared to $6,900,000 for the comparable period in 2024. The revenues in 2025 reflect the royalties paid by AIRMED from the commercialization of Effex in stem cell mobilization in The U. S. The revenues in 2024 primarily reflect a portion of the upfront payments received under the Gloria license agreement. And the milestone payment achieved under the Gloria license agreement which collectively amounted to $5,900,000 as well as $900,000 of net revenues from product sales of Effexxa in The U. S. Cost of revenues for the quarter ended 03/31/2025 was immaterial compared to cost of revenues of $1,500,000 for the comparable period in 2024. The cost of revenues in 2025 reflect sublicense fees on royalties paid by AIRMET from the commercialization of a [indiscernible] In stem cell mobilization in The U. S. The cost of revenues in 2024 primarily reflects sublicense fees. On a milestone payment received under the Gloria Biosciences license agreement and royalties on net product sales of Ofexxa in The U. S. As well as amortization of intangible assets and cost of goods sold on product sales.

23m 20s

Research and development expenses, for the quarter ended 03/31/2025, were $1,600,000 compared to $2,500,000 for the comparable period in 2024. The decrease resulted primarily from lower expenses related to motixafortide due to the out licensing of U. S. Rights to AIRMID. As well as a decrease in payroll and share based compensation compensation. Primarily due to a decrease in headcount. There were no sales and marketing expenses for the quarter ended March 31, 2025 compared to $6,300,000 for the comparable period in 2024. The decrease resulted primarily from the shutdown of U. S. Commercial operations in the fourth quarter of twenty twenty four following the AIRMADE out licensing transaction. Net income for the quarter ended 03/31/2025 were $5,100,000 compared to a net loss of $700,000 for the comparable period in 2024. The increase in net income stems primarily from non operating income associated with the reevaluation of warrants on our balance sheet. As of 03/31/2025, the company had cash, cash equivalents and short term bank deposits of $26,400,000 And with that, I'll turn the call back over to Phil.

24m 52s

Thank you, Molly and thank you to everyone joining this call. We will continue to update you on our progress identifying new assets over the course of the year. With that, we have now concluded the formal part of our presentation. Operator, we will now open the call to questions.

25m 7s

Thank you. Ladies and gentlemen, at this time we will begin the question and answer session. Your questions will be pulled in the order they are received. Please stand by while we poll for your questions. The first question is from Joe Pantginis of H. C. Wainwright. Please go ahead.

25m 41s

Hi everybody good morning good afternoon can you hear me? Yes we can. Great. Thank you. So first a couple of questions on the balance sheet and the P and L if you don't mind. So first, wanted to check on the cash runway stated Does this include any new asset coming in for projected development costs on your end, which you also stated these costs also be offset by potential milestones and effects to royalties.

26m 8s

Yes, it does.

26m 11s

Okay. Then second could you elaborate what I think is know? No. No. That that's fine. Look. I mean, I know there's a bit of vagary there, because we don't know what the asset is yet. You have never better visibility, but that that's definitely good to know. So, no, that that's helpful. And then regarding overall P and L costs, have the costs from the November restructuring worked their way through the P and L already? Yes absolutely. Actually, those costs were fully accrued already by the end of twenty twenty four and so there are no more anticipated costs at all in 2025.

26m 46s

Great, wanted to make sure. And then chemo for med pain, I guess first some anecdotal and then some specific questions. So any anecdotes you can add or provide with regard to the sites that have been added? That might be linked to say excitement to join the study and you know the unmet need.

27m 7s

I'm trying to think if we gave that information it's probably in clinicaltrials.org I imagine. I mean the sites in the study originally were Columbia and Brown University. And and and two more sides of me added Beth Israel and Wisconsin.

27m 26s

Yes.

27m 26s

And then and Fred Hutchinson also. About Right.

27m 29s

Participate.

27m 30s

Correct. And Fred Hutch as well. Yes, no more of like the excitement that these sites wanted to join the study, you know, from an anecdotal standpoint, you know. With with with regard to, you know, seeing the opportunities out there and that sort of links to my, you know, amended question to that of, you know, any competition for enrollment in with regard to pancreatic studies out there?

27m 53s

Yes, okay. So yes, the sites definitely are excited to join I think the poster that is going to be presented at ASH will show some of the data at ASCO, sorry. Show some of the exciting data from the pilot phase there is a great figure where you can see one tumor completely disappearing. There's a beautiful figure there. Also, is one in that poster there is one patient where liver met also disappeared. So these are things [indiscernible] as you said, anecdotally or not in all the patients, but these are definitely things that are very exceptional and exciting.

28m 45s

Got it. And then, I guess, couple of looking forward questions. I guess part one is when you talked about the interim analysis at 40% PFS events, was just curious about the communication strategy around this. Is this a canonical, you know, continuous plan type of announcement to the public, or will more data provided? And then second part of the question is, any views on the potential regulatory strategy going forward looking at say breakthrough designation or even the potential to file on the chemo for med tank data based on potential strength.

29m 25s

So I can start take the first part of that question. As you know we're not running the study right. It's a it's a collaborative with Columbia University and the and Columbia is leading it. And so we are somewhat limited, vis a vis their communication strategy. And so we, you know, we have to aligned with their communication strategy. So we certainly in our collaboration agreement we're allowed to put out data once it's published by Columbia. But initially has to be published by Columbia. And so we're limited about as to what we can say right now and how much control we have over it. But of course, we will be putting out that data as soon as it comes out.

30m 4s

With regard to the second part of your question, if based on this study, one could consider going for regulatory approval [indiscernible] to be fair Usually those studies in order to get approval require primary of overall survival, and this study, as you know, has PFS as the primary endpoint. So of course, will depend if the results will be completely outstanding. But I think the that's really more the chances are not very high that based on this study one could get regulatory approval.

30m 42s

Understood. Thanks for all the details guys.

30m 46s

All right. Have a good day, Joe.

30m 50s

The next question is from Justin Walsh of Dillon's Trading. Please go ahead. This is Justin from Trading.

31m 1s

Now that Effexxa is returning to growth but out of your hands, I'm wondering if you can provide any color on what your expectations are and sort of the long term opportunity for the there? I mean, obviously, can't speak for Amirate, of course.

31m 15s

Yes, mean you're so right we can't speak for amirate but I will say that, you know, we we thought all along, I mean, know, we talked a little bit about the size of the market that this was we estimated when it was it was in our hands and it hasn't changed materially that this is overall about a $300,000,000 market, not that our product would take that whole market, but it was a $300,000,000 market and that we would be able to take a substantial portion of that market.

31m 42s

And so you just look at the entire opportunity, I think that you could infer from that that this is an opportunity in the $100 plus million range. And so I think that's more or less what you could say as far as how you see the revenues of this product going up over the next number of years. Again, are our estimations having nothing to do with Aramed. I can't speak for Aramed, but the were sort of our estimations throughout. And, you know, if you take the that sort of curve going up over the next number of years, think that you can, you know, sort of extrapolate from that how we see this asset if we're getting an 18% to 23% royalty on it as we move forward. I hope that helps us. That's about as much as I can say.

32m 33s

Yeah, no it does. And maybe one quick follow-up. Curious what your thoughts are on the the current trajectory of the cell and gene therapy fields. I think there's been a lot of kind of headwinds from a funding perspective and maybe some of the initial commercial opportunities haven't been quite as high as people have hoped.

32m 54s

But of course, this is still potentially curative opportunities out there for a lot of these So curious as you guys follow the space what your thoughts are from a high level?

33m 5s

Yes, mean I think that we just do the same a little some headwinds at the beginning and etcetera. But you know, this is a long term play. We didn't expect that effects to would immediately enter the market as far as from a sickle cell disease perspective. We see it long term as you know think the headwinds have got to the gene therapy.

33m 28s

That's what I'm saying, the gene therapy, absolutely. So because of obviously there are headwinds in the gene therapy, the use of mobilization agents is obviously going to be limited as But I think that we always saw this as a longer term play. And we have you know, there's there's we have composition of matter coverage well into, you know, 02/1941. And so I think that we did see this as sort of a an a very significant upside to the asset over the next number of years, maybe not initially, but because this is curative, I think we've seen Chief therapy is really taking hold. And then therefore Afexta as well, moving in because it you know, we see it as a superior mobilization agent.

34m 14s

And allowing the gene therapy companies to, you know, to reduce their costs of goods sold. We see that as far as the patients being able to mobilize many more cells in many fewer sessions etcetera. So for all of those reasons we do see this as a potential significant upside for the asset.

34m 34s

Great. Thanks for taking the question.

34m 36s

Okay.

34m 39s

The next question is from John Wandermosten of Zacks. Please go ahead. Great, thank you. And good morning and afternoon to you guys. The do we expect a proportion of license revenues FX to continue at the rate that we saw? The first quarter? What was that $255,000,000 to like $1,400,000 Should we expect that to to go on? So you're saying the ratio of royalty revenues to to FX to revenues? I just want to make sure I understand your question. Yes. Yes, the license revenues to product revenues, about 18% or so I guess which is on the low of your Yes. Mean, are this is very typical of a license deal. They're tiered revenue. So until we reach a certain level of revenue, it affects the reach a certain level of revenues, it will stay at 80% and it will go up to the next year and then to the next year. The next tier. I mean, also have milestone based payments as well. I think that it's a total of up to $87,000,000 in milestone payments. So those payments as well could potentially inert to us over the next number of years. But so we're expecting both royalty revenues on a regular basis and milestone payments if we reach the milestones that are set forth in the agreement.

36m

Okay. And then what's the visibility on the milestones And I know you've got a couple of different sources, Gloria, Gamida Cell, for that.

36m 9s

Not be able to tell me the timing, but maybe just the milestone type or, you know, whatever kind of visibility you can provide us as as we forecast out? On that on future milestones?

36m 19s

Yes.

36m 19s

So because this is a commercial stage asset, the milestones are primarily, commercial based, right? Not development based and not regulatory based but commercial based. But that's about as much as I can tell you.

36m 33s

Okay. I mean, are there any, like, geographic related milestones if if if expands? And I'm talking about also on Gloria as well. Yes. Mean, there are some, yeah, I mean, are you talking about the Airmid agreement or the Gloria agreement? So I because I think I'm Keith, either one really, just, you know, in terms of the potential geographic expansion.

36m 53s

Right. So the Glory agreement has both commercial milestones and development and regulatory milestones. Because there are a number of additional territories, China, Japan, Korea that require some development work and also some regulatory work. So that has a different set of milestones as well as commercial milestones. I believe the AMR agreement also has both indication based milestones as well as geographic milestones.

37m 26s

Okay. And a question on search. Again, I know you're keeping things pretty close to the vest on that. But I wanted to see what your thought process was. And I guess one of the aspects would be, looking for either well validated mechanisms or novel molecules Do you take a stand on either one of those sides of things? I mean, obviously, there's benefits to each one.

37m 49s

We're looking at everything. I think that we're doing a large and comprehensive search, with the help of consultants and we've identified a number of potential assets and we're working to diligence these programs. We're also need to be as a smaller company, we need to be opportunistic. So we do have, obviously, a set of of of principles that are guiding us as far as the search, but we're also trying to be nimble and opportunistic as well. And so I can't give you a clear answer to that. I think that, you know, the answer is that we're looking at everything.

38m 27s

Okay. And just one more question on that aspect and again you're probably not going share the whole thing with me, but there's also looking at small markets with little to no competition or deep markets where there's an unmet need that you you can address? Is that when you talk about your principles, is that something that you look at as well? On those two axes?

38m 47s

We're looking at everything. I do want to add, I mean, I think that we're looking for programs that have a relatively short pathway and a lean clinical development program in order to get to a value creating event. So I think that that's sort of something that could help you understand what we're looking at. I think we're not looking at massive indications that require an enormous a large phase two or phase three or anything like that. We We're looking at more modest programs again that have a short pathway, a short clinical development pathway and a lean clinical development program. I think that's our ideal type of asset that we're looking at. Okay.

39m 29s

Thank you, Phil. I appreciate it.

39m 31s

Okay. Have a great day.

39m 35s

This concludes the question and answer session. Before I ask, Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin in two hours after the conference In The U. S, please call 809-0634. In Israel, please call 039255904. Internationally, please call 97239255904. Mister Serlin? Would you like to make your concluding statement?

40m 9s

Yes. Thank you, operator. In closing, we are excited about this new vision for BioLineRx and we are working diligently to identify identify new assets for in licensing and development that would expand our pipeline and give us additional opportunities for value creation. We believe this path forward best positions us to create value for our shareholders while developing knowledge novel new therapies for patients with cancer and serious rare diseases. Thank you very much for your continued interest in BioLineRx. We look forward to providing our next comprehensive quarterly update in August. Be safe and have a great day.

40m 47s

Thank you. This concludes the BioLineRx first quarter twenty twenty five conference call. Thank you for your participation. You may go ahead and disconnect.

Key Insights

BioLineRx completed an exclusive out-licensing agreement with Aramid Pharma for Effexxa (motixafortide), resulting in an upfront payment, potential significant commercial milestones, and royalties; Effexxa sales returned to growth in Q1 2025, generating $1.4M in sales and $300K in royalty revenue.
The company has significantly reduced its operating cash burn by over 70% (from $40M to less than $12M annually) following the shutdown of U.S. operations and headcount reductions; cash position at the end of Q1 2025 was $26.4M, with a projected runway through the second half of 2026.
BioLineRx is focused on evaluating early clinical and late preclinical stage assets in oncology and rare disease, aiming for efficient development paths funded partly by milestone and royalty income; a definitive announcement on new assets is expected later in 2025.
The ongoing randomized Phase 2b PDAC (pancreatic cancer) trial of motixafortide, sponsored by Columbia University and supported by Regeneron and BioLineRx, is enrolling patients with full enrollment planned for 2027; interim analysis is planned at 40% PFS events, with promising pilot data showing a 64% partial response rate and median PFS of 9.6 months.
Q1 2025 financials: revenues were $300K (from royalties), R&D expenses decreased to $1.6M, no sales/marketing expenses post-restructuring, and net income was $5.1M (vs. a $700K loss in Q1 2024), primarily due to non-operating income from warrant revaluation; future revenue expected from both royalties (18–23%) and up to $87M in milestone payments.

Recent Transcripts

Q1 2025 marked cost reductions, strong cash runway, and Effexxa royalty revenue growth.

BioLineRx secured a transformative licensing deal, streamlining operations and extending cash runway into 2026.

Mar 31

Q4 2024

Licensing Agreement

$10M upfront, $87M milestones, 18-23% royalties

Cash Runway

Extended to 2026

Market Cap: $339M
IPO Date: 7/27/11
CEO: Mr. Philip A. Serlin CPA, CPA, M.B.A., MBA
Fulltime Employees: 28
Sector: Healthcare
Industry: Biotechnology
Country: IL
Exchange: NASDAQ Capital Market

Peers

$0.00

Watchlist

$0.00

Earnings

Report Date

May 27, 2025

Reported Revenue

11.7M

Beat +543.08%

Avg 1d Change

4.57%

Report Period

Q1 2025

Reported EPS

1.4

Beat +265.48%

Implied Move 1d

85.08%

Transcript

9m 41s

10m 37s

12m 17s

13m 37s

15m 11s

16m 35s

18m 14s

19m 41s

21m 12s

However, we have now seen it return to growth in late Q1 and early Q2. Now let me turn the call over to Molly provide a financial update. Molly, please go ahead.

21m 24s

Thank you, Phil. It is our practice.

21m 26s

I will only go over the most significant items in our financial statement. Revenues, cost of revenues, research and development expenses, sales and marketing expenses, net loss, and cash.

21m 40s

23m 20s

24m 52s

25m 7s

25m 41s

26m 8s

Yes, it does.

26m 11s

26m 46s

27m 7s

27m 26s

Yes.

27m 26s

And then and Fred Hutchinson also. About Right.

27m 29s

Participate.

27m 30s

27m 53s

28m 45s

29m 25s

30m 4s

30m 42s

Understood. Thanks for all the details guys.

30m 46s

All right. Have a good day, Joe.

30m 50s

The next question is from Justin Walsh of Dillon's Trading. Please go ahead. This is Justin from Trading.

31m 1s

31m 15s

31m 42s

32m 33s

32m 54s

But of course, this is still potentially curative opportunities out there for a lot of these So curious as you guys follow the space what your thoughts are from a high level?

33m 5s

33m 28s

34m 14s

34m 34s

Great. Thanks for taking the question.

34m 36s

Okay.

34m 39s

36m

Okay. And then what's the visibility on the milestones And I know you've got a couple of different sources, Gloria, Gamida Cell, for that.

36m 9s

Not be able to tell me the timing, but maybe just the milestone type or, you know, whatever kind of visibility you can provide us as as we forecast out? On that on future milestones?

36m 19s

Yes.

36m 19s

36m 33s

36m 53s

37m 26s

37m 49s

38m 27s

38m 47s

39m 29s

Thank you, Phil. I appreciate it.

39m 31s

Okay. Have a great day.

39m 35s

40m 9s

40m 47s

Thank you. This concludes the BioLineRx first quarter twenty twenty five conference call. Thank you for your participation. You may go ahead and disconnect.

Key Insights

BioLineRx completed an exclusive out-licensing agreement with Aramid Pharma for Effexxa (motixafortide), resulting in an upfront payment, potential significant commercial milestones, and royalties; Effexxa sales returned to growth in Q1 2025, generating $1.4M in sales and $300K in royalty revenue.
The company has significantly reduced its operating cash burn by over 70% (from $40M to less than $12M annually) following the shutdown of U.S. operations and headcount reductions; cash position at the end of Q1 2025 was $26.4M, with a projected runway through the second half of 2026.
BioLineRx is focused on evaluating early clinical and late preclinical stage assets in oncology and rare disease, aiming for efficient development paths funded partly by milestone and royalty income; a definitive announcement on new assets is expected later in 2025.
The ongoing randomized Phase 2b PDAC (pancreatic cancer) trial of motixafortide, sponsored by Columbia University and supported by Regeneron and BioLineRx, is enrolling patients with full enrollment planned for 2027; interim analysis is planned at 40% PFS events, with promising pilot data showing a 64% partial response rate and median PFS of 9.6 months.
Q1 2025 financials: revenues were $300K (from royalties), R&D expenses decreased to $1.6M, no sales/marketing expenses post-restructuring, and net income was $5.1M (vs. a $700K loss in Q1 2024), primarily due to non-operating income from warrant revaluation; future revenue expected from both royalties (18–23%) and up to $87M in milestone payments.